The latest price target for Amylyx Pharma (NASDAQ:AMLX) was reported by Goldman Sachs on July 12, 2024. The analyst firm set a price target for $4.00 expecting AMLX to rise to within 12 months (a possible 80.99% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Amylyx Pharma (NASDAQ:AMLX) was provided by Goldman Sachs, and Amylyx Pharma maintained their neutral rating.

The last upgrade for Amylyx Pharmaceuticals Inc happened on July 24, 2023 when Goldman Sachs raised their price target to $49. Goldman Sachs previously had a neutral for Amylyx Pharmaceuticals Inc.

The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharma was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

While ratings are subjective and will change, the latest Amylyx Pharma (AMLX) rating was a maintained with a price target of $3.00 to $4.00. The current price Amylyx Pharma (AMLX) is trading at is $2.21, which is out of the analyst’s predicted range.